

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 14/11/2018

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52(4), 52(5), 52 (7) and 54 (2) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The unaudited financial results of the Company for the half year ended 30th September, 2018 along with the Limited Review Report for that period issued by the Statutory Auditors SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015.
- iv. A statement pursuant to Regulation 52(7) of SEBI (LODR), 2015.
- v. A disclosure under Regulation 54(2) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited


Anand Shah
Compliance Officer
DIN: 00597145



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,
The Board of Directors,
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
Mumbai

Dear Sir,

Re: Limited Review of Un-audited Financial Results for the Half Year ended 30th September, 2018 in respect of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Introduction

We have reviewed the accompanying statement of unaudited financial results of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) for the half year ended 30th September, 2018 this statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a Report on these financial statements based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e Ind AS prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **SHANKARLAL JAIN & ASSOCIATES LLP**
CHARTERED ACCOUNTANTS

Firm Registration No. 109901W/W100082

SATISH JAIN

PARTNER

M. No. 048874



Place : MUMBAI

Dated : 14/11/18

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE BALANCE SHEET AS AT 30 September 2018

(Amount in INR)

Particulars	Note No.	As at 30 Sept 2018 (Unaudited)	As at 31 March 2018 (Audited)
I. ASSETS			
1 Non-current assets			
(a) Property, Plant & Equipment	2	29,172,005	-
(a) Non-current investments	3	248,995,479	248,995,479
2 Current assets			
(a) Cash and cash equivalents	4	903,440	23,387
(b) Other current assets	5	407,951	45,198
TOTAL		279,478,875	249,064,064
II. EQUITY AND LIABILITIES			
1 Equity			
(a) Share capital	6	100,000	100,000
(b) Other Equity	7	(779,742)	(2,769,928)
2 Non-current liabilities			
(a) Financial Liabilities			
(i) Long-term borrowings	8	250,400,000	250,150,000
3 Current liabilities			
(a) Financial Liabilities			
(i) Other financial liabilities	9	29,481,117	1,533,992
(b) Current tax liabilities & Provisions	10	277,500	50,000
TOTAL		279,478,875	249,064,064

For Genlink Pharma Solutions Private limited

Anand Shah

Anand Shah
Chairman
DIN: - 00597145
Navi Mumbai

Susheel Koul

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Somnath Bomble

Somnath Bomble
Chief Financial Officer
Navi Mumbai

Date: 13-11-2018



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED
 (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)
STANDALONE STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDING 30 September 2018

(Amount in INR)

Particulars	Refer Note No	For the period ended 30 Sept 2018 (Unaudited)	For the year ended 31 March 2018 (Audited)
I REVENUE			
Revenue from operations	11	3,000,000	-
Total Revenue		3,000,000	-
II EXPENSES			
Finance costs	12	53,235	18,539
Depreciation and amortisation expenses	13	7,995	-
Other expenses	14	248,584	505,728
Total expenses		309,814	524,267
III Profit/(Loss) before tax (I-II)		2,690,186	(524,267)
IV Tax expense			
Current tax		700,000	-
(Excess)/Short Provision for Tax		-	30,680
V Profit/(Loss) after tax (III-IV)		1,990,186	(554,947)
VI Earnings Per Share			
-Basic & Diluted		199.02	(55.49)

For Genlink Pharma Solutions Private limited

Anand Shah

Anand Shah
Chairman
DIN: - 00597145
Navi Mumbai

Susheel Koul

Susheel Koul
Managing Director
DIN: - 00925887
Navi Mumbai

Somnath Bomble

Somnath Bomble
Chief Financial Officer
Navi Mumbai

Date: 13.11.2018



November 15, 2018

To
Mr. Anand Shah,
Compliance Officer,
Genlink Pharma Solutions Private Limited
1704, 17th Floor, Kesar Solitaire,
Plot No. 5, Sector 19,
Sanpada, Navi Mumbai - 400 705,
Maharashtra, India.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR), 2015 for the Half year ended September 30, 2018.

In compliance with the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 for Secured Redeemable Non-Convertible Debentures it is certified as under:

We, Vistra ITCL (India) Limited are acting as a Debenture Trustee for the debenture programme of Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) issue aggregating to Rs. 25 Crores of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"


With reference to the above, we have received the following documents and noted its contents without verification:

1. Financial results for the half year ended September 30, 2018.
2. Disclosure pursuant to Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2018.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.

Yours sincerely,
For Vistra ITCL (India) Limited



Authorized signatory

Place: Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED


(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

- 1. Credit rating** - The Company's NCDs have been rated as "SMERA BB-" by SMERA Ratings Limited. There has been no change in the credit rating of the Company.
- 2. Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- 3. Debt-equity ratio** - nil
- 4. Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- 5. Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- 6. Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
- 7. Debt service coverage ratio** - NIL
- 8. Interest service coverage ratio** - NIL
- 9. Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares
- 10. Capital redemption reserve/debenture redemption reserve** - NIL
- 11. Net worth** - The net worth of the Company is Rs. -6,73,274/-
- 12. Net profit after tax**
Net profit after tax of the Company is Rs 19, 96, 654/-
- 13. Earnings per share**
Earnings per share of the Company is Rs 199.66/-

For Genlink Pharma Solutions Private Limited

Anand Shah
Compliance Officer
DIN: 00597145



Office: 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email genlinkinfo@gmail.com www.genlinkpharma.com
CIN: U74110 MH 2016 PTC 280765

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the half year ended 30th September, 2018, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited

Anand Shah
Compliance Officer
DIN: 00597145



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)


DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015

We hereby stated that the Company maintains as on 30th September, 2018 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 563,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited

ast

Anand Shah
Compliance Officer
DIN: 00597145

